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Introduction: Evidences of biologics-free disease control after discontinuing adalimumab (ADA) in rheumatoid
arthritis (RA) patients in clinical practice have not been sufficiently investigated. Purpose of this study is to
investigate whether disease activity score 28 (DAS28)- erythrocyte sedimentation rate (ESR) remission was preserved
after discontinuation of ADA in patients with RA.
Methods: This is an observational but not a randomized controlled study. Among 197 RA patients who initiated
with combination of ADA with concomitant MTX, 69 (35%) acquired DAS28 (ESR) < 2.6 for at least 24 weeks. Of
those 69 patients, 51 went on ADA discontinuation with their consent, and finally 50 of those with follow-up of >
24 weeks were evaluated. The effect of discontinuing ADA on clinical disease activity, functional disability and
radiographic progression were evaluated by DAS28 (ESR), the clinical disease activity index (CDAI) and the simplified
disease activity index (SDAI), by a health assessment questionnaire-disability index (HAQ-DI) and by the modified
total Sharp score (mTSS), respectively.
Results: The mean age of the participants was 59.5 years with the mean disease duration of 7.1 years. Out of the
50 patients, 29 (58%) were maintained in DAS28 (ESR) < 2.6 at 24 weeks after discontinuing ADA. A logistic
regression analysis showed that DAS28 (ESR) at baseline significantly predicted a DAS28 (ESR) < 2.6 maintained after
discontinuation of ADA, and a receiver-operating characteristic (ROC) analysis showed that the cut-off value of
DAS28 (ESR) at discontinuation was 2.16. The mean HAQ-DI at six months after discontinuing ADA was 0.1 in
patients who kept in DAS28 (ESR) < 2.6, and 94.9% (37/39) showed no evidence of radiographic progression (> 0.5
per year of a change in mTSS) at 1 year.
Conclusions: It was possible to maintain DAS28 (ESR) < 2.6 after discontinuation of ADA without functional and
radiographic progression and very low DAS28 (ESR) at the discontinuation was associated with successful ADA-free
DAS28 (ESR) < 2.6 in patients with RA.
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The therapeutic strategy against rheumatoid arthritis
(RA) has been considerably improved by clinical applica-
tion of biological agents, including tumor necrosis factor
(TNF) inhibitors. In the Treat-to-Target (T2T) state-
ment, Smolen et al. reported that remission (REM) or
low disease activity (LDA) has become a realistic target
to maximize long-term health-related quality of life in
patients with RA [1]. T2T recommends that patients
who achieve REM or LDA continue medication to maintain
these conditions, based on the evidence of non-biological
disease-modifying anti-rheumatic drugs (DMARDs). How-
ever, corresponding evidence concerning biologics is not
sufficiently available to date. Meanwhile, other recom-
mendations announced by the European League Against
Rheumatism (EULAR) mention that tapering biological
drugs may be considered if a patient is in persistent REM
with synthetic DMARDs after tapering glucocorticoids
(GCs) [2].
RA is an autoimmune disease that is associated with
erosive joint destruction, progressive functional deterior-
ation, systemic complications and high mortality [3], re-
quiring long-term care to avoid long-standing and
disabling polyarthritis and persistent deformity, thus lead-
ing to substantial socioeconomic burden and impairment
of quality of life. In addition, continuous use of biologics
not only spurs an increase in the total medical cost but
also may increase the risk of serious infections [4].
Furthermore, it may be difficult for patients to accept
the idea of never ending treatment. This is one of the
biggest obstacles for the acceptance of biologics. Other
patients may become skeptical about continuing treat-
ment once they reach clinical remission. To date, rheu-
matologists have encouraged patients to continue
treatment without clear evidence to support this
practice.
The HONOR (Humira discontinuation without func-
tional and radiographic damage progressioN follOwing
sustained Remission) study was conducted to elucidate
clinical, functional and radiographic outcomes after dis-
continuation of adalimumab (ADA). Fifty patients with
either early or established RA participated after their
stable disease activity score using 28 joints based on
erythrocyte sedimentation rate (DAS28 (ESR)) <2.6 in-
duced with ADA with concomitant methotrexate (MTX)
was maintained for at least 24 weeks. The purpose of
this study is to investigate whether ADA-free disease
control is possible in patients with RA to address three
questions: 1) what characterizes patients who can retain
DAS28 (ESR) <2.6 even after discontinuation of ADA;
2) what is the effect of ADA discontinuation on radio-
graphic progression as well as functional disability; and
3) whether it is effective to re-administer ADA to pa-
tients with exacerbation.Methods
Patients
Male and female adult patients (age >18 years) who met
the 1987 American College of Rheumatology (ACR) cri-
teria for RA [5] initiated ADA treatment between July
2008 and April 2011. Treatment with ADA 40 mg bi-
weekly was initiated towards DAS28 (ESR) <2.6 induction
in those patients who had an insufficient response to
MTX (mean 9 mg/week) whenever appropriate in our
clinical practice setting. Patients who had been maintained
at DAS28 (ESR) <2.6 with MTX and ADA for at least 24
weeks were enrolled in the discontinuation study with
their informed consent. DAS28 (ESR) remission in this
study was defined as lower than 2.6 without GCs and
non-steroidal anti-inflammatory drugs (NSAIDs) or COX-
II inhibitors (coxibs), but with MTX therapy at a stable
dose. Patients who achieved DAS28 (ESR) <2.6 and
maintained that level for at least 24 weeks went on ADA
discontinuation and thereafter were subject to analysis
after at least another 24 weeks of follow-up. MTX was
maintained at a stable dose after discontinuing ADA dur-
ing the study period, unless the patient was having exacer-
bation, defined as DAS28 (ESR) >3.2 during the follow-up
period. We decided to use a single value rather than
change between two values for the exacerbation criteria
for our comprehensive handling. Restarting ADA was
recommended for patients with exacerbation and was
done with their agreement.
The HONOR study [UMIN000006669] was approved
by the ethics review board of the University of Occupa-
tional and Environmental Health, Japan. The study was
conducted in compliance with the Helsinki Declaration.
Patient disposition
Of the 197 patients who initiated ADA (40 mg s.c. every
other week) with concomitant MTX (mean ± SD: 8.78 ±
3.02 mg/week) under the conventional Japanese national
insurance system between July 2008 and April 2011, 69
patients (35.0%) achieved and maintained a DAS28
(ESR) <2.6 for at least 24 weeks, the criteria for discon-
tinuation (Figure 1). Of those 69 patients, 18 patients
who agreed to participate in this study but did not agree
to discontinue ADA continued on ADA for at least an-
other 24 weeks (a total of at least one year) in DAS28
(ESR) <2.6 and, thus, served as the control. The
remaining 51 patients discontinued ADA, but one pa-
tient was excluded from the evaluation because it had
not been 24 weeks since she discontinued ADA at the
time of data cut-off. All 50 of the eligible patients com-
pleted the primary study period of 24 and 52 weeks.
Efficacy assessments
Clinical assessments were performed at the initiation of
ADA treatment, at the withdrawal of ADA, and at 24
> 1 year 
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Figure 1 Flow diagram of patients with rheumatoid arthritis
treated with adalimumab and methotrexate, and then
discontinued ADA after fulfilling the pre-specified conditions.
ADA, adalimumab; HONOR, Humira discontinuation withOut
functional and radiographic damage progressioN follOwing
sustained Remission; REM, remission.
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was assessed by DAS28 (ESR) [6], the simplified disease
activity index (SDAI) [7] and the clinical disease activity
index (CDAI) [8]. Physical function was assessed at the
initiation of ADA treatment, withdrawal of ADA, and 6
and 12 months after withdrawal by using the disability
index of the Health Assessment Questionnaire (HAQ-
DI) [9]. Radiographs of both the hands and feet were
obtained at the initiation of ADA treatment, withdrawal
of ADA and 12 months after withdrawal. Radiographs
were scored by two independent readers according to
the van der Heijde’s modified total Sharp score (mTSS)
[10]. For patients who restarted ADA due to exacerba-
tion, efficacy assessments were made at the time of
restart.
Outcome measures
The primary outcome measure was the percentage of
patients who maintained DAS28 (ESR) <2.6 at week 24
without ADA. The secondary outcome measures in-
cluded: the percentage of patients who maintained clin-
ical remission in CDAI (≤2.8) or SDAI (≤3.3); the
percentage of patients who maintained clinical low dis-
ease activity (LDA) in CDAI (≤10), SDAI (≤11), as well
as DAS28 (ESR) (≤3.2) at week 24; the proportions of
patients with CDAI, SDAI or DAS28 (ESR) remission at
week 52; functional remission as defined by HAQ ≤0.5
at week 24 and/or 52, and with structural remission asdefined by the change in mTSS (ΔμTSS) ≤0.5 at week 52
(one year).
Statistical analysis
Baseline demographic characteristics, disease activity
and physical functional status were compared between
patients who entered the study and the rest of the pa-
tients who initiated treatment with ADA between 24 July
2008 and 4 April 2011 using the Fisher’s exact test or
Wilcoxon rank sum test, as appropriate. A similar com-
parison was made between patients who entered the study
and those who did not enter despite DAS28 (ESR) <2.6
with MTX and ADA (the control group).
The associations between variables at the start of ADA
discontinuation and 24 weeks maintenance of DAS28
(ESR) <2.6 without ADA were examined in a univariate
logistic regression procedure. The variables investigated
included duration of ADA administration until the with-
drawal, and C-reactive protein (CRP), DAS28 (ESR),
SDAI, CDAI and HAQ at the start of ADA discontinu-
ation. A receiver operating characteristics (ROC) curve
analysis was conducted to determine cut-off points of
variables at the study entry for maintaining DAS28
(ESR) <2.6 for 24 weeks without ADA.
The Wilcoxon rank sum test was employed to test sta-
tistically significant differences in disease activity and
functional states between sub-groups. The Wilcoxon
signed rank test was used to detect statistically signifi-
cant changes in radiographic progression and functional
outcomes over time. All reported P values are two-sided
and not adjusted for multiple testing. The difference of a
P value <0.05 was considered to be significant. The last
observation carried forward (LOCF) was used for miss-
ing clinical or functional values after the start of ADA
discontinuation. Liner extrapolation was used to deter-
mine ΔmTSS at one year, when patients exacerbated
and, thus, restarted ADA or other biological agents. The
analyses were performed using JMP® 9.0.3 (SAS Institute
Inc., Cary, NC, USA) or Prism® 5.0d (GraphPad Software
Inc., San Diego, CA, USA).
Results
Baseline characteristics of the patients
Representative baseline characteristics in patients who
entered the discontinuation study (n = 51) and those
who did not (n = 146) are shown in Table 1. The mean
age of the 51 patients was 59.5 years with mean disease
duration of 7.1 years, thus indicating that the population
included patients with long-established disease. The
mean DAS28 (ESR) score was 5.1, implying that most
patients had active disease despite treatment with MTX.
Furthermore, because the mean annual progression of
mTSS between symptom onset and initiating ADA was
estimated as 11.5/year, addition of TNF inhibitors to
Table 1 Baseline demographic and disease characteristics of the patientsa
Not maintained DAS28
(ESR) <2.6 for 24 weeks
(n = 146)
Maintained DAS28 (ESR) <2.6 for 24 weeks (n = 69)
Discontinued ADA (n = 51) Pb Continued ADA (control) (n = 18) Pc
Age, year 61.1 ± 11.6 59.5 ± 11.2 0.3910 64.8 ± 10.4 0.0513
Gender, F:M 127:19 40:11 0.1742 14:4 1.0000
Disease duration, year 9.4 ± 10.3 7.1 ± 9.9 0.0356 6.7 ± 10.1 0.7375
RF, U/mL 137.2 ± 248.5 109.0 ± 143.0 0.5539 283.5 ± 550.5 0.1400
TJC, 0 to 28 8.9 ± 6.7 8.1 ± 6.6 0.4014 7.6 ± 5.4 0.9727
SJC, 0 to 28 7.5 ± 5.5 6.4 ± 5.0 0.1770 6.7 ± 4.5 0.6214
PGA, 0 to 100 mm 53.4 ± 24.8 39.0 ± 24.2 0.0008 47.8 ± 24.7 0.2185
EGA, 0 to 100 mm 39.6 ± 22.7d 31.5 ± 21.3 0.0398 34.7 ± 19.6g 0.4636
CRP, mg/dl 2.89 ± 4.07 2.27 ± 3.71 0.1460 1.61 ± 1.58 0.3817
ESR, mm/hour 51.9 ± 32.4 43.2 ± 33.6 0.0574 45.6 ± 25.0 0.4318
DAS28 (ESR) 5.57 ± 1.27 5.06 ± 1.26 0.0183 5.33 ± 1.25 0.3528
MMP-3, ng/ml 313 ± 363 217 ± 339 0.0301 333 ± 233 0.0005
HAQ, 0 to 3 1.37 ± 0.77e 0.91 ± 0.67 0.0003 1.27 ± 0.51h 0.0295
MTX, mg/wf 8.85 ± 3.11 8.96 ± 2.72 0.8937 9.61 ± 1.97 0.3480
aExcept where indicated otherwise, values are the mean ± SD; bnot maintained DAS28 (ESR) <2.6 for 24 weeks versus maintained DAS28 (ESR) <2.6 for 24 weeks/
Discontinued ADA; cmaintained DAS28 (ESR) <2.6 for 24 weeks/Discontinued ADA versus maintained DAS28 (ESR) <2.6 for 24 weeks/Continued ADA (control);
dN = 72; eN = 143; fthe mean ± SD were determined including those without concomitant administration of MTX by handling as zero; gN = 10; hN = 16. CPR, C-
reactive protein; DAS28, disease activity score; EGA, evaluator’s global assessment of disease activity; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment
Questionnaire; MMP-3, matrix metalloproteinase-3; MTX, methotrexate; PGA, patient’s global assessment of disease activity; RF, rheumatoid factor; TJC; tender joint
count; SJC, swollen joint count.
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disease activity. However, mean MTX dose was relatively
low (mean ± SD: 8.78 ± 3.02 mg/week), since the MTX
dose for RA had been approved as up to 8 mg/week by
the Japanese government by February 2011 and there-
after up to 16 mg/week. The study participants had a
shorter disease duration, a lower score on HAQ and
lower disease activity than the group of patients who did
not participate. Patients who met the criteria for discon-
tinuation but did not agree to discontinue ADA served
as the control, continuously receiving ADA (n = 18).
The study group had a lower score on the HAQ in com-
parison to the control group (Table 1). Additionally, the
positive ratio for rheumatoid factor was 83.7%, for anti-
CCP autoantibody was 79.3%, and double negative was
12.7% in all 197 patients. There were no significant dif-
ferences in autoantibody status among the groups (data
not shown).
Clinical outcome
Twenty-nine of the 197 total patients (14.7%) who
started ADA, or of the 50 participants (58.0%) who
discontinued ADA after maintaining DAS28 <2.6 for at
least 24 weeks, achieved a DAS28 (ESR) <2.6 that
persisted for more than 24 weeks after the discontinu-
ation (Figures 1 and 2A). However, 21 of the 50 patients
(42%) failed to maintain DAS28 (ESR) <2.6 for 24 weeks
after ADA discontinuation. Twelve of those patients(24%) experienced exacerbation defined as DAS28
(ESR) >3.2 within a 24-week ADA-free period (Fig-
ure 2B). Six of the 12 patients agreed to restart ADA (40
mg/every other week (e.o.w) with a stable MTX dose)
while the other six patients did not agreed to restart
ADA but three agreed to increase MTX (8 to 14, 10 to
14, and 12 to 14 mg/week, respectively). Among the six
patients who restarted ADA, two (33%) attained DAS28
<2.6 again and five (83%) reached DAS28 (ESR) <3.2;
however, only one patient (16%) attained DAS28 ≤2.16
at 24 weeks after restarting ADA. Among the three pa-
tients who increased MTX but did not restart ADA,
none achieved DAS28 <3.2 at 24 weeks after increasing
MTX. Among the three patients who did not agreed to
restart ADA nor to increase MTX, one achieved DAS28
<3.2 at week 52. Overall, 6/12 patients (50%), who failed
to maintain DAS28 (ESR) <3.2 at week 24, in re-
induction achieved DAS28 (ESR) <3.2; however, only
2/12 (16.7%) reached DAS28 (ESR) <2.6 and 1/12 (8.3%)
reached DAS28 (ESR) ≤2.16 within the following 24
weeks. Restarting ADA due to relapse was not associ-
ated with any harmful effects, including skin reaction,
serious adverse events, serious infection or withdrawal
due to adverse events. On the other hand, patients who
restarted ADA had a better response than patients who
did not restart ADA but only increased MTX. In the











































































Figure 2 Time course of DAS28 (ESR) in patients who discontinued adalimumab. The plots show individual data. A) Time course of DAS28
(ESR) at the baseline when adalimumab was initiated, at the HONOR study entry when adalimumab was withdrawn and at the primary endpoint
after 24 weeks follow-up in 29 patients who maintained the DAS28 (ESR) <2.6 after discontinuation of adalimumab for at least 24 weeks. B) Time
course of DAS28 (ESR) at the baseline when adalimumab was initiated, at the HONOR study entry when adalimumab was withdrawn, at the
primary endpoint after 24-weeks follow-up and after methotrexate dose escalation and/or adalimumab restart in 21 patients in whom DAS28
(ESR) exceeded 2.6 within 24 weeks of adalimumab discontinuation. DAS28 (ESR), disease activity score by using 28 joints based on erythrocyte
sedimentation rate; MTX, methotrexate.
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and 24 in relation to DAS28 (ESR) <2.6 or <3.2 at week
24 among the 50 participants. When agreement on
ΔDAS28 (ESR) <0.6 and DAS28 (ESR) <2.6 at week 24
was assessed, 25 patient fulfilled both, five fulfilled only
ΔDAS28 (ESR) <0.6, five fulfilled only DAS28 (ESR) <2.6
and fifteen fulfilled neither. When agreement on ΔDAS28
(ESR) <0.6 and DAS28 (ESR) <3.2 at week 24 was
assessed, 30 patients fulfilled both, no one fulfilled only
ΔDAS28 (ESR) <0.6, 8 fulfilled only DAS28 (ESR) <2.6,
and 12 fulfilled neither. Thus, all patients who did not
maintain DAS28 (ESR) <3.2 at week 24 could not main-
tain ΔDAS28 (ESR) <0.6, as well.
Identification of predictors for maintaining DAS28 (ESR) <2.6
after ADA discontinuation
A univariate logistic regression analysis was conducted
on clinical variables and ADA administration duration
before discontinuation in weeks. The CRP, DAS28 (ESR),
SDAI and CDAI at study entry were found to affect the
maintenance of DAS28 (ESR) <2.6. DAS28 (ESR) gave
the best fit with statistical significance (P = 0.0004). Thelogistic regression analysis showed that the ROC analysis
indicated that the cut-off point of DAS28 (ESR) at study
entry was 2.16. Grouping patients based on this cut-off
point revealed that the mean DAS28 (ESR) at 24 weeks
was significantly higher for patients in whom disease ac-
tivity had been DAS28 (ESR) >2.16 at the time of ADA
discontinuation (P = 0.0017). As a matter of fact, the
percentage of patients who maintained DAS28 (ESR)
<2.6 at 24 weeks after discontinuation of ADA was
78.1% (25/32) of the patient group with DAS28 (ESR)
≤2.16 at study entry, and only 2.2% (4/18) of the patient
group with 2.6 >DAS28 (ESR) >2.16 respectively. The
activity of RA with various indices, and each element,
such as TJC, SJC, CRP, ESR, PGA and EGA between
groups with or without DAS28 (ESR) ≤2.16 at discon-
tinuation is presented in Table 2.
As for matrix metalloproteinase-3 (MMP-3) concen-
tration at initiation and discontinuation of ADA, or
at 24 weeks after discontinuation, we identified no
significant difference between the two groups
according to DAS28 (ESR) ≤2.16, 2.6, or 3.2 at week
24, respectively.
Table 2 Time course of composite measures and remission rate stratified by DAS28 (ESR) at discontinuation of ADA
DAS28 (ESR) ≤2.16 at discontinuation (n = 32) 2.16 <DAS28 (ESR) <2.6 at discontinuation (n = 18)
Week 0 Week 24 Week 0 Week 24
mean ± SD median (IQR) mean ± SD median (IQR) mean ± SD median (IQR) mean ± SD median (IQR)
TJC28 0.06 ± 0.25 0 (0, 0) 1.28 ± 3.27 0 (0, 1) 0.22 ± 0.55 0 (0, 0) 1.39 ± 2.09 0 (0, 2.5)
SJC28 0.03 ± 1.77 0 (0, 0) 0.41 ± 0.98 0 (0, 0) 0.0 ± 0.0 0 (0, 0) 1.17 ± 2.33 0 (0, 1)
PGA (mm) 5.41 ± 6.38 2 (0, 10) 9.75 ± 12.15 4.5 (0.3, 15.8) 8.72 ± 15.08 4 (1.5, 7.5) 16.17 ± 23.63 5 (0.75, 27)
EGA (mm) 2.25 ± 3.62 1 (0, 2.8) 7.22 ± 12.13 1.5 (0, 9.5) 2.50 ± 3.07 2 (0, 3.25) 10.72 ± 16.57 5.5 (0, 10.5)
ESR (mm/hr) 9.78 ± 4.11 9 (6.3, 12) 15.78 ± 10.07 14 (10, 18.8) 24.39 ± 9.05 24.5 (17.5, 32) 39.33 ± 20.55 37 (21.5, 53.75)
CRP (mg/dl) 0.11 ± 0.17 0.04 (0.01, 0.11) 0.35 ± 0.65 0.1 (0.05, 0.30) 0.11 ± 0.22 0.04 (0.03, 0.08) 0.22 ± 0.23 0.15 (0.04, 0.2)
CDAI 0.86 ± 1.00 0.4 (0.03, 1.5) 3.38 ± 5.95 1.0 (0.1, 3.0) 1.34 ± 1.83 0.6 (0.275, 1.7) 5.24 ± 7.32 2.2 (0.075, 9.2)
SDAI 0.97 ± 1.01 0.45 (0.2, 1.8) 3.74 ± 6.23 1.1 (0.3, 4.2) 1.44 ± 1.81 0.8 (0.3, 1.775) 5.45 ± 7.37 2.55 (0.275, 0.2)]
DAS28 (ESR) 1.65 ± 0.34 1.70 (1.45, 2.00) 2.30 ± 1.11 2.00 (1.80, 2.43) 2.41 ± 0.15 2.46 (2.27, 2.54) 3.24 ± 1.14 2.78 (2.54, 3.64)
HAQ 0.14 ± 0.23 0 (0, 0.3) 0.18 ± 0.39 0 (0, 0.1) 0.38 ± 0.38 0.31 (0, 0.66) 0.40 ± 0.44 0.25 (0, 0.78)
mTSS 27.86 ± 61.96 8 (2.5, 23) 64.41 ± 111.33 9 (0.5, 88)
n/N percent n/N percent n/N percent n/N percent
DAS28 (ESR) <2.6 32/32 100% 25/32 78.1% 18/18 100% 4/18 22.2%
DAS28 (ESR) <3.2 32/32 100% 27/32 84.4% 18/18 100% 11/18 61.1%
CDAI ≤2.8 31/32 96.9% 24/32 75.0% 15/18 83.3% 11/18 61.1%
SDAI ≤3.3 31/32 96.9% 23/32 71.9% 15/18 83.3% 11/18 61.1%
Boolean definition 25/32 78.1% 21/32 65.6% 15/18 83.3% 10/18 55.6%
CDAI, clinical disease activity index; CRP, C-reactive protein; DAS28 (ESR), disease activity score by using 28 joints based on erythrocyte sedimentation rate; EGA,
evaluator’s global assessment; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; LOCF, last observation carried forward; mTSS, modified
total Sharp score, Boolean definition: ACR/EULAR 2010 definition criteria of clinical remission (TJC ≤1, SJC ≤1, PGA ≤1 cm, CRP ≤1 mg/dl); PGA, patient’s global
assessment; SDAI, simplified disease activity index; SJC, swollen joint count; TJC, tender joint count.
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Radiographic progression was assessed in 39 patients at
ADA discontinuation through 12 months thereafter.
Twelve months had elapsed since ADA discontinuation
in 40 of the 50 evaluable patients, but data were missing
in four patients. Although a slight increase in the mean
ΔmTSS was observed, 94.9% (37/39) showed no evi-
dence of radiographic progression (ΔmTSS ≤0.5) at one
year after the discontinuation. The ΔmTSS >0.5 was ob-
served within the first year of ADA discontinuation in
two patients, so that their radiographic progression was
determined by linearly extrapolating changes using their
radiographic scores at exacerbation (data not shown).
One of the two patients was a 57 year-old woman with
symptom duration of 73 months, and her mTSS was 31
at withdrawal of ADA, which increased to 34 at exacer-
bation only 13 weeks after withdrawal. The other patient
was a 65 year-old woman with symptom duration of 10
months, and her mTSS was 10 at withdrawal of ADA,
which exacerbated to 11 at 38 weeks later, although it
was a less than clinically relevant radiographic progres-
sion (>3/year).
Functional outcome
The difference in the mean baseline HAQ-DI at the ini-
tiation of ADA therapy was not significant betweenthose who maintained in DAS28 (ESR) <2.6 and those
who failed (P = 0.2693). The mean functional improve-
ment in HAQ-DI observed at the time of ADA discon-
tinuation was maintained at 24 weeks in the sub-group
with ADA-free remission, while a slight non-significant
worsening was observed in the sub-group that failed to
maintain in DAS28 (ESR) <2.6 without ADA.
Discussion
The present study demonstrated that 29/197 (14.7%) of
all the patients with MTX + ADA achieved DAS28
(ESR) <2.6 that persisted for more than six months after
ADA discontinuation; this represents 58% of the patients
in whom discontinuation of ADA was attempted (with
maintenance of MTX). This group maintained ADA-free
DAS28 (ESR) <2.6 without functional impairment or
radiographic progression over 24 weeks. Although the
sample size is limited, the induction of DAS28 (ESR) <2.6
for at least 24 weeks by treatment with ADA and MTX
could lead some patients with long-standing RA to dis-
continuation of ADA, not only in a randomized controlled
study setting but also in daily clinical practice.
However, not all patients with stable DAS28 (ESR) <2.6
with ADA and MTX could be maintained in that state
after ADA discontinuation. A small increase in the mean
DAS28 (ESR) was observed for patients in whom disease
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discontinuation. Furthermore, these patients experienced
disease exacerbation within 24 weeks after ADA discon-
tinuation at a higher rate than the subgroup with DAS28
(ESR) ≤2.16. This result warrants close monitoring of dis-
ease activity after discontinuation and, more importantly,
very low DAS28 (ESR) at study entry appears to be a pre-
requisite for the successful biologics-free maintenance of
DAS28 (ESR) <2.6, which is analogous with the remission
induction by Remicade in RA (RRR) study that was previ-
ously reported [11]. Additionally, we determined that
MMP-3 concentration was not predictive for maintenance
of DAS28 (ESR) <2.6 or 3.2 after discontinuation, while it
was significantly different between groups with or without
discontinuation.
An evaluation of whether restarting anti-TNF therapy
would allow recovery of good clinical outcomes in pa-
tients who lost response after switching to MTX mono-
therapy would be valuable. Brocq et al. reported that
relapsed patients consistently regained remission status
after reintroducing ADA and there were no major ad-
verse events in these patients [12]. The HONOR study
also found that most of the exacerbated patients
achieved a clinical response following ADA restart with-
out any adverse events. On the other hand, dose escal-
ation of MTX tended to be less effective.
Discontinuation of synthetic DMARD has not been
recommended, since RA patients in clinical remission
had twice as many flare-ups when synthetic DMARDs
were discontinued, causing difficulties in reintrodu-
cing remission and a halt in damage, whereas similar
sufficient evidence has not been seen for the bio-
logical DMARDs. Recently, a double-blind, random-
ized controlled study was carried out to determine
the optimal protocol for treatment initiation with
ADA with concomitant MTX in patients with early
RA (OPTIMA) [13]. In part of the protocol, the out-
comes of withdrawal or continuation of ADA were
assessed in patients who achieved a stable LDA target
after 26 weeks of initially being assigned to treatment
with ADA and MTX. Another trial conducted in
Germany (HIT HARD) addressed the question of
whether an early induction therapy with a subsequent
step down strategy leads to a long-term clinical effect
in recent onset RA patients in comparison to initial
and continued MTX monotherapy [14]. Those trials
revealed that the early induction therapy with ADA
and MTX followed by withdrawal of ADA led to loss
of the response gained with the initial combination
treatment in a subgroup of patients in both studies,
but not in all patients. However, it should be empha-
sized that, among patients with very early RA in the
OPTIMA and HIT HARD trials, some could be con-
trolled well even with MTX monotherapy.The targets of long-term RA management are to sup-
press inflammation, arrest progressive joint destruction
and ultimately retain physical function. It is conceiv-
able to alter the progression of RA by modulating the
T-cell responses at a very early stage of RA [15]. The
results of the RRR and HONOR trials indicate a possi-
bility of halting the disease process in the course of
long-standing RA [11]. Both trials used MTX as an an-
chor drug and then maintenance therapy was consid-
ered to be crucial not only for the maintenance of
biologics-free disease control, but also in terms of sup-
pressing the immunogenicity of ADA when combined
and retaining radiographic inhibitory effects, even after
discontinuation [16].
The HONOR study was an observational study with a
rather small sample size and a short period of follow-up;
thus, whether DAS28 (ESR) <2.6 for at least 24 weeks in
patients with long-term RA is sufficient to achieve stable
biologics-free maintenance of DAS28 (ESR) <2.6 may re-
quire further assessments. Especially, the effect of the
dose of concomitant MTX may be of great interest,
since in our study we could use a relatively lower dose
of MTX due to the limitation of the dose approved by
the Japanese national insurance system. The distinctive
feature of this study is that the patients had a relatively
long disease history (mean 7.1 years) and were not lim-
ited only to early RA patients. Yet, it is of clinical as well
as medical-economic significance that the present study
demonstrated the possibility of ADA-free maintenance
of a good condition, such as clinical remission or other
comprehensive good outcomes, in a certain patient
population with long-standing RA, even in established
RA patients.
Of course, it should be emphasized that possible dis-
ease control after discontinuation of biological anti-
rheumatic drugs is still shown only in preliminary trials,
and it should not be used for patients without sufficient
informed consent of the risk of worsened outcome. Al-
though the effectiveness of re-administration for the ma-
jority of the patients with exacerbation is encouraging, it
is more important to evaluate the patients’ condition
regularly after discontinuing a TNF inhibitor. Especially,
the requirement to re-administer ADA and/or increase
MTX should be carefully and repeatedly assessed; other-
wise, discontinuation of biologics even after achieving
stable DAS28 (ESR) <2.6 should be discouraged. How-
ever, these findings may help comfort patients who have
to discontinue biologics for any reason, including finan-
cial problems or subsequent complications, such as ma-
lignancies or infection.
Conclusions
It was possible to maintain DAS28 (ESR) <2.6 even after dis-
continuation of the ADA without functional deterioration
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of patients. Very low DAS28 (ESR) at discontinuation was
associated with successful maintenance of DAS28 (ESR)
<2.6 without ADA. Further investigation in a larger popula-
tion is required to clarify the long-term possibility of ADA-
free maintenance of DAS28 (ESR) <2.6 and the medical or
socio-economic benefit derived by clinical remission
discontinuation.
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